China Pharma Announces Pricing of $5 Million Registered Direct Offering

Rhea-AI Summary

China Pharma (NYSE American: CPHI) priced a registered direct offering of 2.5 million common shares at $2.00 per share, targeting gross proceeds of $5 million before fees and expenses. The company plans to use net proceeds for working capital and general corporate purposes.

The offering is expected to close on or about July 23, 2026, with FT Global Capital acting as exclusive placement agent. The transaction is being conducted under an effective Form F-3 shelf registration, with a prospectus supplement to be filed with the SEC.

Positive

• $5 million gross proceeds to support working capital and corporate purposes
• Financing executed under an effective Form F-3 shelf registration
• Exclusive placement agent engagement with FT Global Capital

Negative

• Issuance of 2.5 million new shares implies equity dilution for existing holders
• Net proceeds reduced by placement agent fees and offering expenses

News Explained

The priced offering is not yet closed; if completed, 2.5 million shares would dilute existing ownership, and net proceeds would be below five million dollars.

The offering is priced but not yet closed; if the planned issuance occurs, existing holders' percentage ownership would fall because the total share count would increase.

A registered direct is a negotiated sale to selected investors; here, the stated $5 million is gross, while placement-agent fees and other expenses reduce cash received for working capital and general corporate purposes.

Using the quarter ended March 31, 2026 as the basis, the $5 million gross offering equals 8138.6 days of the last reported operating cash use, versus 274.2 days represented by $168,474 of reported cash and equivalents.

Sources and calculations

• China Pharma Announces Pricing of $5 Million Registered Direct Offering (2026-07-22)
• Dilution (undated)
• Registered direct offering (undated)
• China Pharma Holdings, Inc. first-quarter 2026 fundamentals (2026Q1)

• Offering gross vs quarterly operating cash outflow, in days of cash use $5,000,000 / ($55,292 / 90) = [object Object]
• Cash and equivalents vs quarterly operating cash outflow, in days of cash use $168,474 / ($55,292 / 90) = [object Object]

Market reaction after registered direct offering: CPHI -78.89% in the Jul 22 session

-78.89%

171 alerts

-78.89% Session close to close

+21.9% Peak Tracked

-84.3% Trough Tracked

$328.23M Market Cap

1.1x Rel. Volume

In the Jul 22 session, CPHI declined 78.89%, reflecting a significant negative market reaction. Argus tracked a peak move of +21.9% during that session. Argus tracked a trough of -84.3% from its starting point during tracking. Our momentum scanner triggered 171 alerts that day, indicating very high trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock dropped -78.9% in the session following this news. The prior offering event produced a -4....

Analysis

The stock dropped -78.9% in the session following this news. The prior offering event produced a -4.58% 24-hour reaction. That historical comparison highlighted dilution as a financing risk, while the stated working-capital purpose provided operational context without establishing an outcome.

Key Figures

Shares offered: 2.5 million shares Purchase price: $2 per share Gross proceeds: $5 million +4 more

7 metrics

Shares offered 2.5 million shares Registered direct offering

Purchase price $2 per share Registered direct offering

Gross proceeds $5 million Before placement agent fees and other offering expenses

Expected closing July 23, 2026 Offering expected to close on or about this date

Shelf filing date January 12, 2024 Form F-3 shelf registration statement filing

Shelf effectiveness date February 14, 2024 Form F-3 shelf registration statement declared effective

SEC file number 333-276481 Form F-3 shelf registration statement

Previous Offering Reports

1 past event · Latest: Dec 13 (Negative)

Same Type Pattern 1 events

Date	Event	Sentiment	24h Move	Catalyst
Dec 13	At-the-market offering	Negative	-4.6%	At-the-market equity offering permitting up to $600,000 in common-stock sales

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

The tag-specific history showed one prior offering event followed by a negative 24-hour reaction.

Key Terms

registered direct offering, shelf registration statement, form f-3, prospectus supplement

4 terms

registered direct offering financial

"pricing of its registered direct offering of 2.5 million shares"

A registered direct offering is a way for a company to sell new shares of its stock directly to select investors with regulatory approval. This method allows the company to raise funds quickly and efficiently without needing a public auction, similar to offering exclusive access to a limited number of buyers. For investors, it often provides an opportunity to purchase shares at a favorable price, while giving the company immediate access to capital.

shelf registration statement regulatory

"made pursuant to the Company's "shelf" registration statement on Form F-3"

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

form f-3 regulatory

"registration statement on Form F-3 (File No. 333-276481)"

Form F-3 is a U.S. securities filing that lets eligible foreign companies pre-register and then quickly sell shares or other securities to raise money, because they already meet ongoing reporting and size tests. For investors it signals that the company is up-to-date with regulatory disclosure and has an efficient way to issue new securities — similar to a pre-approved credit line — which can mean faster capital raises but also potential dilution of existing holdings.

prospectus supplement regulatory

"A prospectus supplement and accompanying base prospectus describing the terms"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HAIKOU, China, July 22, 2026 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma" or the "Company"), a fully-integrated specialty pharmaceuticals company in China, today announced that the pricing of its registered direct offering of 2.5 million shares of its common stock ("Common Shares"), at a purchase price of $2 per share.

The gross proceeds from the offering will be $5 million, before deducting placement agent fees and other offering expenses.

The Company intends to use the net proceeds from this offering for working capital and general corporate purposes.

The offering is expected to be closed on or about July 23, 2026. 

FT Global Capital, Inc. is acting as the exclusive placement agent for the offering.

The offering was made pursuant to the Company's "shelf" registration statement on Form F-3 (File No. 333-276481), filed with the U.S. Securities and Exchange Commission (the "SEC") on January 12, 2024 and declared effective on February 14, 2024. A prospectus supplement and accompanying base prospectus describing the terms of the offering will be filed with the SEC and is available on the SEC's website at www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Safe Harbor Statement

This press release contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including those regarding China Pharma's Holdings Inc.'s beliefs and expectations about its business strategy, growth outlook, and operational plans are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. Several factors could cause actual results to differ materially from those contained in any forward-looking statement. These factors include, but are not limited to: (i) capital and credit market volatility, (ii) local and global economic conditions, (iii) anticipated growth strategies and integration plans, (iv) regulatory changes or governmental approvals, and (v) future business development, operational results, and financial performance of China Pharma Holdings Inc. In some cases, forward-looking statements can be identified by words or phrases such as "may," "will," "expect," "anticipate," "target," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to," or other similar expressions. All information provided in this press release is as of the date of this press release, and China Pharma Holdings Inc. undertakes no obligation to update such information, except as required under applicable law.

About China Pharma Holdings, Inc.

China Pharma Holdings, Inc. is a specialty pharmaceutical company that develops, manufactures and markets a diversified portfolio of products focused on conditions with a high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective, high-margin business model is driven by market demand and supported by eight scalable GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding nationwide distribution network across all major cities and provinces in China. The Company's wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., is located in Haikou City, Hainan Province. For more information about China Pharma Holdings, Inc., please visit http://www.chinapharmaholdings.com. The Company routinely posts important information on its website.

Contact:
China Pharma Holdings, Inc.                              
Phone: +86-898-6681-1730 (China)                                            
Email: hps@chinapharmaholdings.com

View original content:https://www.prnewswire.com/news-releases/china-pharma-announces-pricing-of-5-million-registered-direct-offering-302832160.html

SOURCE China Pharma Holdings, Inc.

FAQ

What did China Pharma (CPHI) announce about its $5 million stock offering on July 22, 2026?

China Pharma announced pricing of a registered direct offering of 2.5 million common shares at $2 per share, for $5 million in gross proceeds. According to China Pharma, the transaction is under its effective Form F-3 shelf registration and uses an exclusive placement agent.

What is the share price and size of the new China Pharma (CPHI) registered direct offering?

The offering is priced at $2.00 per common share, covering 2.5 million shares for $5 million in gross proceeds. According to China Pharma, this amount is before deducting placement agent fees and other offering-related expenses tied to the transaction.

When is the China Pharma (CPHI) $5 million registered direct offering expected to close?

The offering is expected to close on or about July 23, 2026, subject to customary conditions. According to China Pharma, FT Global Capital is serving as exclusive placement agent for this transaction under the company’s effective shelf registration.

How will China Pharma (CPHI) use the proceeds from its July 2026 stock offering?

China Pharma plans to use the net proceeds for working capital and general corporate purposes. According to China Pharma, the $5 million gross proceeds will be reduced by placement agent fees and other offering expenses before these corporate uses are funded.

Is the China Pharma (CPHI) registered direct offering made under an existing shelf registration?

Yes. The offering is made under China Pharma’s Form F-3 shelf registration, filed January 12, 2024 and effective February 14, 2024. According to China Pharma, a prospectus supplement and base prospectus describing terms will be filed with the SEC.

Who is the placement agent for the China Pharma (CPHI) July 2026 registered direct offering?

FT Global Capital is acting as the exclusive placement agent for the offering. According to China Pharma, the firm is handling the registered direct placement of 2.5 million common shares priced at $2 per share under the company’s existing shelf registration.